Increased local failure risk with prolonged radiation treatment time in head and neck cancer treated with concurrent chemotherapy

Head and Neck

Volumn 36, Issue 8, 2014, Pages 1120-1125

  Cannon, Donald M ^a   Geye, Heather M ^a   Hartig, Gregory K ^a   Traynor, Anne M ^a   Hoang, Tien ^a   McCulloch, Timothy M ^a   Wiederholt, Peggy A ^a   Chappell, Richard J ^a   Harari, Paul M ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

accelerated repopulation; chemoradiotherapy; head and neck cancer; prognostic factors; treatment time

Indexed keywords

BEVACIZUMAB; CETUXIMAB; CISPLATIN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; CHEMORADIOTHERAPY; CHEMOTHERAPY; CLINICAL TRIAL (TOPIC); DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RADIATION DOSE DISTRIBUTION; RADIATION DOSE FRACTIONATION; RADIATION TREATMENT TIME; RADIOLOGICAL PARAMETERS; RETROSPECTIVE STUDY; RISK ASSESSMENT; SINGLE DRUG DOSE; TIME; ADVERSE EFFECTS; CARCINOMA, SQUAMOUS CELL; HEAD AND NECK NEOPLASMS; MIDDLE AGED; MORTALITY; PROCEDURES; PROPORTIONAL HAZARDS MODEL; RADIATION DOSE; SURVIVAL RATE; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY DOSAGE; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84904254142     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.23419     Document Type: Article

References (20)

1. Pignon JP, le Maître A, Maillard E, Bourhis J,; MACH-NC Collaborative Group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009; 92: 4-14.
2. Barton MB, Keane TJ, Gadalla T, Maki E,. The effect of treatment time and treatment interruption on tumour control following radical radiotherapy of laryngeal cancer. Radiother Oncol 1992; 23: 137-143.
3. Fowler JF, Lindstrom MJ,. Loss of local control with prolongation in radiotherapy. Int J Radiat Oncol Biol Phys 1992; 23: 457-467.
4. Van den Bogaert W, Van der Leest A, Rijnders A, Delaere P, Thames H, van der Schueren E,. Does tumor control decrease by prolonging overall treatment time or interrupting treatment in laryngeal cancer? Radiother Oncol 1995; 36: 177-182.
5. Withers HR, Peters LJ, Taylor JM, et al. Local control of carcinoma of the tonsil by radiation therapy: an analysis of patterns of fractionation in nine institutions. Int J Radiat Oncol Biol Phys 1995; 33: 549-562.
6. Nishimura Y, Nagata Y, Okajima K, et al. Radiation therapy for T1,2 glottic carcinoma: impact of overall treatment time on local control. Radiother Oncol 1996; 40: 225-232.
7. Le QT, Fu KK, Kroll S, et al. Influence of fraction size, total dose, and overall time on local control of T1-T2 glottic carcinoma. Int J Radiat Oncol Biol Phys 1997; 39: 115-126.
8. Fu KK, Pajak TF, Trotti A, et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 2000; 48: 7-16.
9. Overgaard J, Hansen HS, Specht L, et al. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. Lancet 2003; 362: 933-940.
10. Overgaard J, Mohanti BK, Begum N, et al. Five versus six fractions of radiotherapy per week for squamous-cell carcinoma of the head and neck (IAEA-ACC study): a randomised, multicentre trial. Lancet Oncol 2010; 11: 553-560.
11. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010; 363: 24-35.
12. Bourhis J, Sire C, Graff P, et al. Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 randomised trial. Lancet Oncol 2012; 13: 145-153.
13. Sher DJ, Posner MR, Tishler RB, et al. Relationship between radiation treatment time and overall survival after induction chemotherapy for locally advanced head-and-neck carcinoma: a subset analysis of TAX 324. Int J Radiat Oncol Biol Phys 2011; 81: e813-e818.
14. Dragovic AF, Bonner JA, Spencer SA, Nabell LM, Carroll WR, Caudell JJ,. Impact of average weekly dose of radiation during radiotherapy alone or chemoradiotherapy in head and neck cancer. Head Neck 2011; 33: 1551-1556.
15. Setton J, Caria N, Romanyshyn J, et al. Intensity-modulated radiotherapy in the treatment of oropharyngeal cancer: an update of the Memorial Sloan-Kettering Cancer Center experience. Int J Radiat Oncol Biol Phys 2012; 82: 291-298.
16. Wong WW, Mick R, Haraf DJ, Weichselbaum RR, Vokes EE,. Time-dose relationship for local tumor control following alternate week concomitant radiation and chemotherapy of advanced head and neck cancer. Int J Radiat Oncol Biol Phys 1994; 29: 153-162.
17. Wendt TG, Grabenbauer GG, Rödel CM, et al. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. J Clin Oncol 1998; 16: 1318-1324.
18. Benard VB, Johnson CJ, Thompson TD, et al. Examining the association between socioeconomic status and potential human papillomavirus-associated cancers. Cancer 2008; 113 (10 Suppl): 2910-2918.
19. Gillison ML, D'Souza G, Westra W, et al. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst 2008; 100: 407-420.
20. Lassen P, Eriksen JG, Krogdahl A, et al. The influence of HPV-associated p16-expression on accelerated fractionated radiotherapy in head and neck cancer: evaluation of the randomised DAHANCA 6&38;7 trial. Radiother Oncol 2011; 100: 49-55.